Rinsho Shinkeigaku (Clinical Neurology)

Original Article

Dichloroacetate treatment for adult patients with mitochondrial disease

Kenichi Oishi, M.D.1) 2), Masayuki Yoshioka, M.D.1), Ritsuko Ozawa, M.D.1), Toshiyuki Yamamoto, M.D.1), Yasushi Oya, M.D.1), Masafumi Ogawa, M.D.1) and Mitsuru Kawai, M.D.1)

1)Department of Neurology, National Center Hospital for Mental, Nervous and Muscular Disorders, National Center of
Neurology and Psychiatry, 2)Division of Endocrinology/Metabolism, Neurology and Hematology/Oncology,
Department of Clinical Molecular Medicine, Kobe University School of Medicine

We report beneficial and adverse effects of sodium dichloroacetate (DCA) in three adult Japanese patients with mitochondrial disease: a 21-year-old male with involuntary movements, optic atrophy, hearing loss, and convulsions (patient 1), a 28-year-old man with mental deterioration, hemianopia, hearing disturbance, and convulsions (patient 2), and a 50-year-old woman with hearing disturbance, generalized muscle atrophy, and insulin dependent diabetes mellitus (patient 3). A3243G mutation was found in patient 2 and patient 3. Oral administration of DCA improved consciousness level and gait disturbances in patient 1, and ameliorated headaches, easy fatiguability, and muscle cramps in patient 2 and patient 3. DCA normalized high levels of lactate and pyruvate in blood and cerebrospinal fluids in all three patients. In patient 3, daily insulin needs decreased from 38 to 24 units, and urine C peptide increased from an undetectable level to 16μ g/day. In patient 1, DCA 23mg/kg/day had been beneficial without adverse effects and he became free of convulsions for more than 32 months. However, despite of normal lactate and pyruvate, unsteady gait and lethargy developed after 50mg/kg/day treatment for two months and one month in patient 2 and patient 3, respectively. In both patients, deep tendon reflexes disappeared and Romberg sign became positive. Nerve conduction studies confirmed sensory-dominant polyneuropathy and electroencephalogram showed diffuse slow basic activities. Cessation of DCA resulted in recovery of gait and consciousness, but sensory nerve action potentials did not recover in one month. Long term treatment of 50 mg/kg/day DCA may affect adversely the peripheral and central nervous systems in adult patients. Although effective plasma DCA concentration was previously reported as 25∼ 160μ g/ml in patients under 18 years old, plasma DCA concentration of 10.2μ g/ml was sufficient in patient 1. We recommend lower dose of DCA in adult patients than in child patients.

(CLINICA NEUROL, 43: 154|161, 2003)
key words: dichloroacetate, mitochondrial disease, adult patients, consciousness disturbances, peripheral neuropathy

(Received: 24-Dec-02)